RCE to present at the 2023 American College of Cardiology – Late Breaking Clinical Trials

Carlsbad, California (December 20, 2022) – RCE Technologies, Inc. has been accepted to present at the American College of Cardiology – Late Breaking Clinical Trials. The presentation titled, “A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction” will be delivered center stage on March 6, in New Orleans, Louisiana, by Dr. Partho Sengupta, Henry Rutgers Professor of Cardiology and Division Chief of Cardiology at the Rutgers Robert Wood Johnson Medical Center.

The selection process was highly competitive. Presenting our research at the Annual Scientific Session represents a critical contribution to the evolving science and innovative strategies that are central to the experience at ACC.23/WCC.

In Founder & CEO, Atandra Burman’s own words, “Dr. Sengupta will be presenting novel insights from our recent multi-site study, to a live audience of a few hundred clinicians, health care executives and strategic investors in person, with live broadcast worldwide. While the abstract cannot be shared publicly, we anticipate this bringing high visibility to RCE’s scientific validation efforts. We very much appreciate the team’s exceptional effort on the clinical execution and data analysis fronts. This would especially not be possible without the trust and support imparted in RCE by our investors and the timely deployment of capital to keep us on track.”

About RCE:

RCE, an AI based med tech works towards the early detection of heart attacks. We have re-imagined the way cardiac proteins are monitored in the blood using a non-invasive transdermal technique. The instant reporting of one such protein, cardiac Troponin empowers emergency medicine physicians and cardiologists in the early assessment and appropriate risk stratification of patients presenting with chest pain. We currently are conducting clinical studies and undertaking  premarket efforts.